Frequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men by Oliveira, Ana Carolina Soares de et al.
  Universidade de São Paulo
 
2012-09-29
 
Frequency of subtype B and F1 dual infection
in HIV-1 positive, Brazilian men who have sex
with men
 
 
Virology Journal. 2012 Sep 29;9(1):223
http://dx.doi.org/10.1186/1743-422X-9-223
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Outros departamentos - FSP/Outros Artigos e Materiais de Revistas Científicas - IMT
RESEARCH Open Access
Frequency of subtype B and F1 dual infection in
HIV-1 positive, Brazilian men who have sex
with men
Ana Carolina Soares de Oliveira1,2, Rodrigo Pessôa de Farias2, Antonio Charlys da Costa1,2, Mariana Melillo Sauer3,
Katia Cristina Bassichetto4, Solange Maria Santos Oliveira4, Priscilla Ramos Costa3, Claudia Tomiyama3,
Helena Tomoko Iwashita Tomiyama3, Ester Cerdeira Sabino5, Esper Georges Kallas3 and Sabri Saeed Sanabani6,7*
Abstract
Background: Because various HIV vaccination studies are in progress, it is important to understand how often
inter- and intra-subtype co/superinfection occurs in different HIV-infected high-risk groups. This knowledge would
aid in the development of future prevention programs. In this cross-sectional study, we report the frequency of
subtype B and F1 co-infection in a clinical group of 41 recently HIV-1 infected men who have sex with men (MSM)
in São Paulo, Brazil.
Methodology: Proviral HIV-1 DNA was isolated from subject's peripheral blood polymorphonuclear leukocytes
that were obtained at the time of enrollment. Each subject was known to be infected with a subtype B virus as
determined in a previous study. A small fragment of the integrase gene (nucleotide 4255–4478 of HXB2) was
amplified by nested polymerase chain reaction (PCR) using subclade F1 specific primers. The PCR results were
further confirmed by phylogenetic analysis. Viral load (VL) data were extrapolated from the medical records of
each patient.
Results: For the 41 samples from MSM who were recently infected with subtype B virus, it was possible to detect
subclade F1 proviral DNA in five patients, which represents a co-infection rate of 12.2%. In subjects with dual
infection, the median VL was 5.3 × 104 copies/ML, whereas in MSM that were infected with only subtype B virus
the median VL was 3.8 × 104 copies/ML (p > 0.8).
Conclusions: This study indicated that subtype B and F1 co-infection occurs frequently within the HIV-positive
MSM population as suggested by large number of BF1 recombinant viruses reported in Brazil. This finding will help
us track the epidemic and provide support for the development of immunization strategies against the HIV.
Introduction
Mutation and recombination are the two main evolu-
tionary forces that generate genetic variation in HIV-1.
Like other human positive-sense RNA viruses, human
immunodeficiency virus (HIV-1) has a high mutation
rate, which in its case is due to the error-prone nature of
the viral reverse transcriptase (3 × 10-5 mutations per
nucleotide per replication cycle) [1,2]. This high rate of
mutation, coupled with a high replication rate (10.3 ×
109 particles per day) [3], allows for the generation and
fixation of a variety of advantageous mutations in a virus
population. These changes are selected in response to
the host immune pressure to enable the virus to resist
the host defense. Recombination is another potential
source of genetic variation that contributes significantly
to the genetic diversification of HIV and could poten-
tially produce more virulent viruses, drug resistant
viruses, or viruses with altered cell tropism that may
reduce the effectiveness of antiretroviral therapy and
may present major challenges for the design of vaccines
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[4]. It has been reported that recombinant viruses in-
cluding the unique recombinant forms (URF) and circu-
lating recombinant forms (CRF), may account for
at least 20% of all HIV infections [5]. The existence of
recombinant viruses is an evidence of simultaneous
infection of multiple viruses during a single transmission
event (co-infection) or from the sequential infection of
viruses during multiple transmission events (superinfec-
tion). Co-infection has been well documented in indivi-
duals that are infected with both HIV-1 and HIV-2 [6,7],
and individuals infected with viruses from different HIV-
1 groups [8], and individuals infected with different
subtypes or recombinant variants [9-16], and with diver-
gent variants of the same subtype from different sources
[17-23]. The consequence of co-infection has significant
implications on antiretroviral resistance and vaccine de-
velopment. Furthermore, it could lead to immunologic
escape and subsequent disease progression [21,24]. Thus,
determining the frequency of dual infections is of great
interest for the clinical management of HIV infection.
Unpublished data from our laboratory found evidence
of an HIV-1 subtype B and F1 dual infected homosexual
patient. Therefore, we attempted to retrospectively
evaluate the frequency of HIV-1 subclade F1 and sub-
type B dual infections in Brazilian recently HIV-1-
infected men who have sex with men (MSM).
Materials and methods
Patients
The subjects in this study were part of a previously
described prospective cohort of recently HIV-1 infected
persons from São Paulo, Brazil [25]. Recent infection
was defined as being infected for less than 170 days
(95% confidence interval: 145–200 days) using the sero-
logic testing algorithm for recent human immunodefi-
ciency virus (HIV) seroconversion (STARHS) strategy
[26]. Forty-one MSM participants were selected for this
study based on the following criteria: infection with a
subtype B virus based on near full-length genome or
partial pol (including complete integrase region) analysis
[27,28], availability of a blood sample from the initial
time point. The details of this cohort and the methods
for identifying recent infection were described elsewhere
[25,27,29]. For this study, evidence for dual infection
was defined as the presence of subclade F1-proviral
DNA in the same blood samples and in the same gen-
omic region that was previously identified for subtype B
infection. Detection of both viruses in a single clinical
sample strongly suggests that the two variants were due
to either co-infection or superinfection. However, only
the frequency of dual infection was concluded in this
study because we do not know whether co-infection or
superinfection originally occurred. Patient data, includ-
ing age, number of CD4-positive T cells, and viral load
(VL) was obtained from the patient medical records
(Table 1). Information on the sexual behaviors, including
the specific number of unprotected sexual acts, sexual
partners, sex acts per partner, the HIV status of a partner
and VL of an HIV-1 positive partner at the time of sex-
ual intercourse are lacking. All study participants signed
an informed consent form, and the project was approved
by the ethics committee of the Federal University of
São Paulo.
Proviral DNA extraction and amplification
All samples used in this study were the same as those
described previously [27]. PMNs were isolated from pa-
tient blood samples collected at the time of enrollment,
and genomic DNA was extracted using a QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany), according to
the manufacturer’s instructions. The proviral DNA was
subjected to nested PCR to amplify a 248 bp fragment of
the integrase gene (pol-IN) using the primers listed in
Table 2. The assay was developed to detect subclade F1
viral isolates with a high sensitivity and specificity. By
analyzing the alignment of complete genome sequences
of different subtypes of HIV-1, the pol-IN gene region
was targeted because it was well conserved within sub-
clade F1 strains, yet has a unique sequence compared to
other HIV-1 subtypes. In the initial PCR, a 266 bp inte-
grase fragment was amplified using an Eppendorf Master
cycler. The PCR condition consisted of an initial de-
naturation step at 95°C for 2 minutes, followed by 35
cycles of 95°C for 30 seconds, 58°C for 30 seconds and
68°C for 1 minute, and a final extension was carried out
at 68°C for 5 minutes. For the nested PCR, 5 μl of the
first PCR reaction was used, and the PCR mix included
subclade F1-specific inner primers (Table 2). The ampli-
fied product was electrophoresed through a 1.5%
(wt/vol) agarose gels containing 0.5 × Tris Borate EDTA
followed by ethidium bromide staining. To allow a more
advanced phylogenetic analysis, another set of forward
primers that were specific for subclade F1 pol region
Table 1 Characteristics of the 41 study MSM subjects
Median age. years (range) 30.6 (18–56)
Median CD4 count . cells/mm3 (range) 564 (198–2449)
Median viral load. log HIV RNA
copies/mL (range)
4.3 X 104 (< 400–39 X104)
Serologies (% positive)*
HHV8 ( LANA) 11 (26.8)
TPHA positive 10 (24.3)
Toxoplasmosis [30] 26 (63.4)
Anti-HCV 0
Anti-HBc (%) 18 (43.9)
* HHV8 Human herpes virus type 8; LANA latency-associated nuclear antigen;
TPHA Treponema pallidum hemagglutination assay; HCV Hepatitis C virus; HBc
Hepatitis B core antigen.
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were designed. These primers were used in combination
with the reverse pol-IN primers to amplify a 1247 bp
L-pol fragment. Amplification and detection of the L-pol
fragment was carried out using the same PCR conditions
as described previously with a modification of the exten-
sion time to 2 minutes.
Isolates that were characterized as subclade F1 by PCR
amplification and DNA sequencing of the pol-IN frag-
ment but failed to be amplified by PCR using the L-pol
specific primers suggested that these isolates may be
recombinant viruses. To address this issue, forward pri-
mers were used to amplify a 727-bp product (denoted as
M-pol). These primers were able to amplify a broad
range of HIV-1 variants including subtype B and F1.
These primers were used in combination with the re-
verse pol-IN primers in a nested PCR assay, using the
same conditions described for the pol-IN PCR assay ex-
cept for an annealing temperature at 55°C and a 2 mi-
nute extension time. Both PCR assays, L-pol and M-pol,
had a sensitivity of 25 and 15 copies per reaction,
respectively. All assays were performed in duplicate for
each fragment using the primer combinations shown in
Table 2. Positive and negative controls (healthy donor
PMNs) were included in each assay. Strict laboratory
precautions were taken to avoid cross contamination.
Specimens that had a clear amplification in each dupli-
cate reaction were considered to be positive.
Sequencing and phylogenetic analysis
The amplified DNA fragments were purified using a
QIAquick PCR Purification Kit (Qiagen, Hilden, Ger-
many) and directly sequenced using second-round pri-
mers and the PRISM Big Dye Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems/
Perkin-Elmer, Foster City, CA) on an automated sequen-
cer (ABI 3130, Applied Biosystems). After excluding
the primer regions, each amplicon was assembled into
a contiguous sequence alignment and edited with the
Sequencher program 4.7 (Gene Code Corp., Ann Arbor,
MI). The alignment of multiple sequences, including
the reference sequences for subtypes A–D, F–H, J and
K (http://hiv-web.lanl.gov), was performed using the
CLUSTAL X program [30] and followed by manual edit-
ing using the BioEdit Sequence Alignment Editor pro-
gram version 5.0.7 [31]. Gaps and ambiguous positions
were removed from the final alignment. The phylogen-
etic relationships were determined by two methods: the
neighbor-joining (NJ) algorithm of MEGA version 5.0
software [32] and maximum likelihood (ML) using
PHYML v.2.4.4 [33]. For the NJ method, trees were con-
structed under the maximum composite likelihood sub-
stitution model and bootstrap re-sampling was carried
out 1000 times. For the ML method, phylogentic trees
were constructed using the GTR + I + G substitution
model and a BIONJ starting tree. Heuristic tree searches
under the ML optimality criterions were performed using
the nearest-neighbor interchange (NNI) branch-swapping
algorithm. The approximate likelihood ratio test (aLRT)
based on a Shimodaira-Hasegawa-like procedure was
used as a statistical test to calculate branch support. Trees
were displayed using the MEGA v.5 package.
Nucleotide sequence accession numbers
The sequences described here have been deposited
(accession numbers pending)
Results
Blood samples were obtained from 41 MSM study parti-
cipants who had been previously characterized as being
infected with HIV-1 subtype B virus (Figure 1) [27]. The
median VL in this cohort was 4.3 × 104 copies/ml
(range, <400-39.3 × 104). The median baseline CD4-
positive T cell count was 564 cells/mm3 (range, 198–
2449 cells/mm3). The age of the subjects ranged from
18 to 56 years, and the median age was 30.6 years. All
patients were treatment-naive at the time of sample
Table 2 Details of PCR primer combinations
N0. Primer Combinations
of Primers
Fragment
amplified
PCR
type
sequence (5’-3’) Primer
Position3
Product
size bp
1 DPSH-O-Fwd1 1+2 pol-IN Outer ATAAGGCACAGGAGGAACATGAAAAATATCACAAC 4246-4280 266
2 DPLINF-O-Rev2 TTTTTTTTTCTGCTGGGATAACTTCTGCTTCTAGG 4512-4478
3 DPSH-N-Fwd 3+4 Nested AGGAGGAACATGAAAAATATCACAAC 4255-4280 248
4 DPINF-N-Rev CTGCTGGGATAACTTCTGCTTCTAGG 4503-4478
5 DPINF-O-Fwd 5+2 L-pol Outer TTTTTTTTTTTCTGATAAATGGACAGTGCAGCCTATACAAT 3247-3285 1265
6 DPINF-N-Fwd 6+4 Nested CTGATAAATGGACAGTGCAGCCTATACAAT 3256-3285 1247
7 B01-Fwd 7+2 M-pol Outer TGGGTTATGAACTCCATCCTG 3238-3258 1274
8 B02-Fwd 8+4 Nested CTGGATTCCTGAGTGGGAGTT 3776-3796 727
The underlined nucleotides (non-HIV-1 specific sequences) are tails at the 5’ end of the outer reverse primers and were added to enhance the nested
amplification with inner reverse primers.
1 Fwd: Forward, 2 Rev: Reverse.
3 Nucleotide position of the primer according to the HXB2 sequence (K03455) numbering.
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collection. The main characteristics of the study popula-
tion are shown in Table 1.
Before processing the patient samples, we wanted to
determine the sensitivity of the subclade F1 specific pri-
mers for the amplification of the pol-IN fragment. This
was performed by using multiple reaction tubes, each
containing 105 copies of HIV-1 subtype B and a known
quantity of subclade F1 partial proviral pol DNA ranging
from 1 × 100 to 1 × 106 copies per reaction. The sensi-
tivity of PCR amplification of the subclade F1 partial
proviral pol DNA was one copy of target per reaction in
a background of 105 copies of HIV-1 subtype B. The
specificity of the nested PCR for subclade F1 was con-
firmed by sequencing the amplified PCR products. Fur-
thermore, this assay was tested on 15 subclade F1 and
25 subtype B patient samples that were previously char-
acterized by partial and near full-length proviral genome
analysis [27,28,34,35]. As shown in Figure 2A, clear
bands at the expected size of 248 bp for subclade F1
were seen in all reactions, but not in the subtype B
strains (Figure 2B).
Having verified the sensitivity and specificity of the
pol-IN primers, we wanted to establish the conditions
and reliability of the L-pol and M-pol primers in ampli-
fying their specific PCR fragments (see Table 2). Thus,
the latter primers were tested against a range of previ-
ously published HIV-1 subtype B, F1 and BF1 proviral
variants [27,28,34-37]. The L-pol primers amplified a
clear product from only subclade F1 isolates (Figure 2C).
Similarly, the M-pol primers amplified a fragment of the
correct size from all BF1 and subclade F1 variants, but
no or weak amplification of multiple products was
observed when the primers were used to assay subtype B
variants (Figure 2D). All products were sequenced to de-
termine the specific subtype.
Using pol-IN nested PCR in our clinical samples, 5 of
41 (12.2%) of the MSM patient samples, already
described to be infected with subtype B, were also found
to be infected with F1 virus. The sequences of the pol-
IN fragment from the five subjects were then compared
with representative sequences from all subtypes available
in the HIV database (year 2005). Consistent with the
results of our pol-IN PCR assay, the ML tree, shown in
Figure 3, indicated that all five sequences clustered to-
gether with the subclade F1 (90% aLRT) reference strain.
The mean intersubject sequence diversity among these
five isolates was 1.1% (range, 0.2–1.7%). As shown in
Figure 1, HIV-1subtype B strains from these 5 MSM did
not demonstrate any evolutionary linkages.
Despite various attempts, amplification of the L-pol
fragment in subclade F1 positive samples was unsuc-
cessful. These results suggested that the 5 MSM were
co-infected with a BF1 recombinant virus. To address
this question, proviral DNA from the samples that were
positive for the pol-IN fragment were subjected to amp-
lification and sequencing of M-pol. We used a combin-
ation of primers that specifically amplified the M-pol
fragment that contained subclade F1 sequence at the 3'
end if these patients were infected with recombinant
virus. This reaction produced either no amplification
or resulted in the amplification of multiple weak frag-
ments with insufficient yield to perform sequencing.
Overall, these results indicated that the 5 MSM patients
are likely infected with both subtype B and F1 HIV-1.
The failure to amplify L-pol and M-pol fragments is
likely a result of the low frequency of subclade F1 pro-
viral DNA.
A comparison of the VLs between single and dual
infected MSM was performed. In subjects with dual in-
fection, the median VL was 5.3 × 104 and ranged from
1.5 × 104 to 12.5 × 104 copies/mL. In MSM that were
infected only with subtype B, the median VL was 3.8 ×
104 copies/mL and ranged from undetectable (<400 cop-
ies/mL) to 39.3 × 104 copies/mL. As observed in other
studies, there results indicated that the VL are statisti-
cally the same [38].
Figure 1 Phylogenetic tree constructed using a maximum-
likelihood method from partial pol region (1279 bp; nt 3822–
5101 of HXB2) of 41 samples from MSM that have previously
been determined to be infected with HIV-1 subtype B
(indicated by black circles) and 37 HIV-1 reference sequences
from the Los Alamos HIV-1 database representing 11 genetic
subtypes. Samples that were identified in this study to host
subclade F1 DNA are indicated with star symbol. For purposes of
clarity, the tree was midpoint rooted. The approximate likelihood
ratio test (aLRT) values of ≥ 90% are indicated at nodes. The scale
bar represents 0.05 nucleotide substitutions per site.
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Discussion
This study describes the prevalence of HIV-1 subtype B
and F1 dual infections in recently infected Brazilian
MSM. Among the 41 subjects studied, 12.2% were posi-
tive for both subtypes B (from previous study) and F1
proviral DNA (current study). These results are not sur-
prising because both viral subtypes and recombinants
are widely circulating in Brazil, which is a country that
offers an excellent setting for such studies. It is probable
that our results have underestimated the true rate of
dual infection in this group. The most likely explanation
for underestimation is that some isolates could have
been undetected by our specific PCR screening method
because of a mismatch at the primer binding sites, low
proviral load, or that the subclade F1 isolates were main-
tained in another reservoir other than the CD4-positive
compartment that was sampled in the peripheral blood.
Additionally, our method only detects dual infection of
subtypes B and F1 when the pol-IN region is subclade
F1. We could have missed some instances of co-
infection if recombination had happened, and the pol-IN
fragment is not subclade F1. Therefore, it is possible that
the dual infection in this group may be higher than what
was observed if we had sequenced a larger region or
sequenced other regions of the viral genome. Our
attempts to amplify larger fragments to determine if
recombination had occurred were unsuccessful, probably
because these subjects were co-infected and maintained
low proviral loads of subclade F1 compared to the sub-
type B viral population. However, because most of the
HIV-1 subclade F1 strains circulating in Brazil contain
recombinant genomes and particularly with recombin-
ation with subtype B [27,34,39], we cannot rule out the
possibility of F1 recombination in the present study. Our
findings also may not be generalizable. This retrospect-
ive study focused on a select, relatively small group of
recently HIV infected MSM that were known to be
infected with subtype B virus. Consequently, the dual
infection rates reported cannot necessarily be extrapo-
lated to other populations of HIV-infected MSM. In
spite of these caveats, we have been able to identify five
cases of dual infection by studying only one genomic
Figure 2 Representative agarose gel of the nested polymerase chain reaction (PCR) produts. Electrophoresis and subsequent ethidium
bromide staining of amplicons from the nested PCR amplification with pol-IN subclade F1-specific primers of the DNA samples known to harbor
HIV-1 subclade F1 (A), and subtype B (B). Amplicons of nested PCR (1247 bp) performed with L-pol subclade F1-specific primers using samples
that were observed to be infected with HIV-1 subclade F1 (solid line), BF1 recombinants with breakpoints located between the PCR primers
(dotted line), and subtype B (dashed line). (C). Amplicons of nested PCR (727 bp) performed with M-pol primers (specific for F1 and BF1 variants)
using samples observed to be infected with HIV-1 subclade F1 (solid line), BF1 recombinants with breakpoints located between the PCR primers
(dotted line), and subtype B (dashed line) (D). M, molecular weight DNA marker (100 bp DNA ladder, Invitrogen).
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region of the HIV genome, similar to the Kenyan study
[38]. In the Kenyan study, the authors observed seven
cases of HIV-1 superinfection among 36 high-risk women
and only five cases of superinfection were detected by
differences in only one gene. Unexpectedly, a lack of de-
tectable HIV-1 dual infections has recently been reported
in a retrospective study of 83 samples from chronically
infected patients on antiretroviral treatment throughout
Figure 3 Phylogenetic tree constructed using a maximum-likelihood method from pol-IN (219 bp ; nt 4269–4488 of HXB2) fragments
from five of the samples isolated from MSM observed to be infected with both subtype B (indicated by black circles) and subclade F1
DNA (indicated by black squares) along with HIV-1 reference sequences from the Los Alamos HIV-1 database representing 11 genetic
subtypes. For purposes of clarity, the tree was midpoint rooted. The approximate likelihood ratio test (aLRT) values of ≥ 70% are indicated at
nodes. The scale bar represents 0.05 nucleotide substitutions per site.
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the KwaZulu-Natal region that has a high HIV prevalence
[40]. The lack of dual infections in this study was
explained by the ability of the immune system to evolve
overtime to eliminate or prevent a second viral infection
during chronic infection [40,41].
Despite a large body of literature, the true prevalence
and the timing of immune selection in HIV co/super-
infection cases have not yet been substantiated by robust
clinical studies and the limited data that do exist have
yielded inconclusive or contradictory findings that par-
tially contribute to the controversies surrounding the
challenge and implications of HIV co/superinfection for
efficient vaccine design [38,42,43]. Our estimates of sub-
type B and F1 dual infection rates are not directly com-
parable to other published studies as each study group
has used different research designs, methodologic
approaches, and different target population for the
search of different HIV-1 subtypes [8,16,44-52]. All to-
gether, these data lend further support to the conclu-
sions that dual infections are an integral part of the
HIV/AIDS epidemic, particularly in countries where
multiple subtypes are circulating in the population [15].
In summary, our data adds to the knowledge of the
prevalence of HIV-1 dual infections caused by HIV-1
subtype B and F1 viruses in MSM subjects and provides
data from a country where such a phenomenon is rarely
documented. Furthermore, these data agree with the
consensus that the presence of two or more HIV-1 sub-
types within an infected individual is relatively frequent
[53,54]. Thus, testing for co-infection and superinfection
and the implementation of effective preventative mea-
sures in the MSM population remains relevant issue.
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